Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Staccato alprazolam, an inhaled medication, in people aged 12 years and older who experience stereotypical prolonged seizures. The study aims to compare a single dose of Staccato alprazolam with a placebo in quickly stopping a seizure within 90 seconds and preventing further seizures for up to 2 hours after treatment. Participants are randomly assigned to receive either one dose of Staccato alprazolam or a matching placebo by inhalation in this double-blind study. This single-dose treatment is given during the outpatient treatment period, and participants are monitored closely to assess seizure control and safety. During the study, participants will have their seizures evaluated for treatment success within 90 seconds and for any recurrence up to 6 hours after dosing. Researchers will also monitor respiratory events and seizure frequency. Participants will have regular assessments, including safety follow-up visits extending up to 19 weeks after treatment, to ensure thorough monitoring of effects and any adverse events.
Actively Recruiting
Researchers are studying adults with fibrosing interstitial lung disease ILD, excluding idiopathic pulmonary fibrosis IPF, who have been diagnosed within the last three years and may be at risk of developing progressive pulmonary fibrosis PPF. The trial aims to evaluate the effects of a medicine called nerandomilast in slowing lung function decline and disease progression in this group. Participants are randomly assigned to one of two groups one takes nerandomilast tablets, and the other takes placebo tablets that look identical but contain no medicine. The study lasts up to about 2 years and 4 months, during which participants take their assigned tablets regularly and undergo scheduled assessments to monitor their lung condition. Throughout the study, participants visit the study site regularly for tests including spirometry to measure forced vital capacity FVC and diffusing capacity of the lungs for carbon monoxide DLCO. High-resolution computed tomography HRCT scans track lung changes over time. Researchers compare these results between groups to assess treatment effects, while monitoring overall health and any side effects.
Actively Recruiting
Researchers are studying the effects of PIPE-791 in adults aged 40 years and older with Idiopathic Pulmonary Fibrosis IPF, a lung disease characterized by progressive scarring. This Phase 2, randomized, double-blind, placebo-controlled global study aims to evaluate the efficacy, safety, tolerability, and how the body processes PIPE-791 in participants who may or may not be receiving other approved IPF treatments. The study is sponsored by Contineum Therapeutics and will enroll approximately 324 participants. Participants will be assigned to one of three groups two different daily oral doses of PIPE-791 or a placebo. The treatment period lasts 26 weeks. The full study duration extends up to 36 weeks, including screening before treatment and follow-up after treatment ends. Participants receive their assigned tablets daily during the treatment phase. Throughout the study, participants will undergo lung function tests such as forced vital capacity FVC, high-resolution CT scans to assess lung fibrosis, and safety monitoring for any side effects or adverse events. Researchers will track changes in lung function and overall health from the start of treatment to week 26, with additional safety follow-up until week 30. The study involves regular visits for assessments, and participant involvement may last up to 36 weeks in total.
Actively Recruiting
Researchers are evaluating the investigational drug omecamtiv mecarbil to see if it can reduce the risk of serious effects related to heart failure, such as hospitalization, heart transplantation, or death, in patients with symptomatic heart failure with severely reduced ejection fraction HFrEF. This Phase 3 trial compares the safety and effectiveness of omecamtiv mecarbil against a placebo in patients with this condition. Participants will be randomly assigned to receive either omecamtiv mecarbil or a placebo. Those in the omecamtiv mecarbil group will take oral tablets twice daily with doses adjusted based on drug levels in their blood 25, 37.5, or 50 mg. The treatment continues until at least 850 participants experience a heart failure event or cardiovascular death. This is a double-blind study, meaning neither participants nor study staff know who receives the drug or placebo. During the study, participants will be monitored up to about 3 years. Researchers will track occurrences of cardiovascular death, heart failure events, device implantations, heart transplants, and strokes. Participants will have regular visits and assessments to monitor their health and study outcomes. Safety and efficacy data will be collected until the study concludes when the required number of events has occurred.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.